- Home
- TAK vs MRNA Comparison
TAK vs MRNA Comparison
Compare TAK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAK | MRNA |
|---|---|---|
| Founded | 1781 | 2010 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.8B | 61.6B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TAK | MRNA |
|---|---|---|
| Price | $20.91 | $221.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 23 |
| Target Price | $23.11 | ★ $138.37 |
| AVG Volume (30 Days) | 2.7M | ★ 16.9M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $5.55 | $8.13 |
| Revenue Next Year | $1.06 | $16.26 |
| P/E Ratio | $41.25 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $13.35 | $22.28 |
| 52 Week High | $20.55 | $254.48 |
Technical Indicators
Market Signals| Indicator | TAK | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 71.84 | 56.30 |
| Support Level | $17.73 | $45.39 |
| Resistance Level | N/A | $254.48 |
| Average True Range (ATR) | 0.33 | 22.75 |
| MACD | 0.09 | -3.28 |
| Stochastic Oscillator | 88.33 | 53.57 |
Price Performance
Historical ComparisonAbout TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.